Oncolytic VSV-IL-2 has enhanced anticancer vaccination adjuvant abilities
Background Heterologous oncolytic virus prime-boost vaccination is emerging as a promising cancer immunotherapy to establish potent antitumor immunity. With their natural ability to specifically destroy cancer cells, oncolytic viruses also allow for direct oncolysis and our team has previously demon...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-05-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/5/e010570.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|